Literature DB >> 7062992

Epidemiologic features of chronic atrial fibrillation: the Framingham study.

W B Kannel, R D Abbott, D D Savage, P M McNamara.   

Abstract

In the Framingham Study 2325 men and 2866 women 30 to 62 years old at entry were followed biennially over 22 years for the development of chronic atrial fibrillation in relation to antecedent cardiovascular disease and risk factors. During surveillance, atrial fibrillation developed in 49 men and 49 women. The incidence rose sharply with age but did not differ significantly between the sexes. Overall, there was a 2.0 per cent chance that the disorder would develop in two decades. Atrial fibrillation usually followed the development of overt cardiovascular disease. Only 18 men and 12 women (31 per cent) had chronic atrial fibrillation in the absence of cardiovascular disease. Cardiac failure and rheumatic heart disease were the most powerful predictive precursors, with relative risks in excess of sixfold. Hypertensive cardiovascular disease was the most common antecedent disease, largely because of its frequency in the general population. Among the risk factors for cardiovascular disease, diabetes and electrocardiographic evidence of left ventricular hypertrophy were related to the occurrence of atrial fibrillation. The development of chronic atrial fibrillation was associated with a doubling of overall mortality and of mortality from cardiovascular disease.

Entities:  

Mesh:

Year:  1982        PMID: 7062992     DOI: 10.1056/NEJM198204293061703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  397 in total

Review 1.  New devices and hybrid therapies and new devices for treatment of atrial fibrillation.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  Ask patients which herbal drugs they smoke as well as eat.

Authors:  T O Cheng
Journal:  West J Med       Date:  2000-02

Review 3.  When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?

Authors:  K M Flegel
Journal:  CMAJ       Date:  1999-04-20       Impact factor: 8.262

4.  Determinants of successful direct current cardioversion for atrial fibrillation and flutter: the importance of rapid referral.

Authors:  A R Houghton; A Sharman; J E Pohl
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

5.  Automatic atrial anti-tachy pacing for the termination of spontaneous atrial tachyarrhythmias: clinical experience with a novel dual-chamber pacemaker.

Authors:  D Vollmann; J Stevens; A B Buchwald; C Unterberg
Journal:  J Interv Card Electrophysiol       Date:  2001-12       Impact factor: 1.900

Review 6.  Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis.

Authors:  S L Kopecky
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 7.  Very low-intensity antithrombotic therapy in atrial fibrillation.

Authors:  B G Koefoed; P Petersen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 8.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

9.  Pharmacological atrial defibrillation via temporarily occluded coronary sinus: first clinical experience and implications for an implantable device.

Authors:  G Vergara; D Catanzariti; F Cozzi; R Accardi; W Spagnolli; L Cammilli
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

Review 10.  Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.

Authors:  S Lévy
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.